• “中国科技期刊卓越行动计划”中文领军期刊
  • 百种中国杰出学术期刊
  • 中国百强报刊
  • RCCSE中国核心学术期刊(A+)
  • 中国自然科学类核心期刊
  • 中国高校百佳科技期刊
  • 中国精品科技期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文(5000)项目来源期刊
  • 入选中国高质量科技期刊分级目录(消化病学)T1级
  • 入选《中国学术期刊影响因子年报(自然科学与工程技术)》Q1区
  • 入选《科技期刊世界影响力指数(WJCI)报告(2022)》
  • “中国科技期刊卓越行动计划”中文领军期刊
  • 百种中国杰出学术期刊
  • 中国百强报刊
  • RCCSE中国核心学术期刊(A+)
  • 中国自然科学类核心期刊
  • 中国高校百佳科技期刊
  • 中国精品科技期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文(5000)项目来源期刊
  • 入选中国高质量科技期刊分级目录(消化病学)T1级
  • 入选《中国学术期刊影响因子年报(自然科学与工程技术)》Q1区
  • 入选《科技期刊世界影响力指数(WJCI)报告(2022)》

胆囊癌临床治疗的现状与展望

刘颖斌, 陈炜

刘颖斌, 陈炜. 胆囊癌临床治疗的现状与展望[J]. 中华消化外科杂志, 2023, 22(1): 81-88. DOI: 10.3760/cma.j.cn115610-20230109-00013
引用本文: 刘颖斌, 陈炜. 胆囊癌临床治疗的现状与展望[J]. 中华消化外科杂志, 2023, 22(1): 81-88. DOI: 10.3760/cma.j.cn115610-20230109-00013
Liu Yingbin, Chen Wei. Current situation and prospect in the clinical treatment of gallbladder cancer[J]. Chinese Journal of Digestive Surgery, 2023, 22(1): 81-88. DOI: 10.3760/cma.j.cn115610-20230109-00013
Citation: Liu Yingbin, Chen Wei. Current situation and prospect in the clinical treatment of gallbladder cancer[J]. Chinese Journal of Digestive Surgery, 2023, 22(1): 81-88. DOI: 10.3760/cma.j.cn115610-20230109-00013

胆囊癌临床治疗的现状与展望

基金项目: 

国家自然科学基金 3213000192

上海申康医院发展中心 SHDC12021101

详细信息
    通讯作者:

    刘颖斌,Email:laoniulyb@163.com

Current situation and prospect in the clinical treatment of gallbladder cancer

Funds: 

National Natural Science Foundation of China 3213000192

Shanghai Shen‑kang Hospital Development Centre SHDC12021101

More Information
  • 摘要:

    胆囊癌预后差,缺乏有效的综合治疗手段,外科治疗是该病最主要的治疗方法。术前精准评估和充分准备,以及术中安全、有效、规范切除肿瘤是治疗成功的关键。重视意外胆囊癌的防范和合理治疗。新辅助或转化治疗能充分发挥化疗、靶向、免疫药物对肿瘤细胞的杀伤作用,达到术前降期或转化目的,提高胆囊癌根治性切除率,改善患者预后。

    Abstract:

    Gallbladder carcinoma is a tumor with poor prognosis and lack of effective comprehensive treatment. At present, surgical resection is still the main treatment for gallbladder carcinoma. Precise evaluation and adequate preparation before surgery, and safe, effective, standar-dized resection are the key points to successful treatment of gallbladder carcinoma. In clinic, there has been a growing appreciation of the prevention and reasonable treatment of incidental gallbladder carcinoma. Neoadjuvant and conversion therapy give full play to the effects of chemotherapy, targeted therapy, and immunotherapy agents on tumor cells, which can achieve the goal of downstage or conversion of tumors before surgery, increasing the radical resection rate, and improving the prognosis of patients.

  • 所有作者均声明不存在利益冲突
    刘颖斌, 陈炜. 胆囊癌临床治疗的现状与展望[J]. 中华消化外科杂志, 2023, 22(1): 81-88. DOI: 10.3760/cma.j.cn115610-20230109-00013.

    http://journal.yiigle.com/LinkIn.do?linkin_type=cma&DOI=10.3760/cma.j.cn115610-20230109-23013

  • [1]

    ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115‑132. DOI:10.33 22/caac.21338.

    [2]

    RakićM, PatrljL, KopljarM, et al. Gallbladder cancer[J]. Hepatobiliary Surg Nutr,2014,3(5):221‑226. DOI: 10.3978/j.issn.2304-3881.2014.09.03.

    [3] 孙旭恒,王一钧,张薇,等.中国胆囊癌流行病学特征与诊治及预后分析(附6 159例报告)[J].中华消化外科杂志,2022,21(1):114‑128. DOI: 10.3760/cma.j.cn115610-20220103-00004.
    [4] 李起,金哲川,张东,等.基于双期增强CT检查影像组学胆囊癌淋巴结转移预测模型构建及其应用价值[J].中华消化外科杂志,2022,21(7):931‑940. DOI:10.3760/cma.j.cn1156 10-20220613-00324.
    [5] 胆道肿瘤专家委员会.CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J].临床肿瘤学杂志,2019,24(9):828‑838. DOI: 10.3969/j.issn.1009-0460.2019.09.014.
    [6] 李茂岚,朱逸荻,吴向嵩,等.精准胆道外科技术与传统手术治疗胆囊癌临床疗效对比研究[J].中国实用外科杂志,2018,38(9):1039‑1044. DOI:10.19538/j.cjps.issn1005-22 08.2018.09.19.
    [7]

    OguraY, TabataM, KawaradaY, et al. Effect of hepatic invasion on the choice of hepatic resection for advanced carcinoma of the gallbladder: histologic analysis of 32 surgical cases[J]. World J Surg,1998,22(3):262‑267. DOI:10. 1007/s002689900380.

    [8]

    AbramsonMA, PandharipandeP, RuanD, et al. Radical resection for T1b gallbladder cancer: a decision analysis[J]. HPB (Oxford),2009,11(8):656‑663. DOI:10.1111/j.14 77-2574.2009.00108.x.

    [9]

    ShindohJ, de AretxabalaX, AloiaTA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study[J]. Ann Surg,2015,261(4):733‑739. DOI:10.1097/SLA.00 00000000000728.

    [10]

    KwonW, KimH, HanY, et al. Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study[J]. Br J Surg,2020,107(10):1334‑1343. DOI: 10.1002/bjs.11618.

    [11] 付佳禄,李起,张东,等.《胆囊癌诊断和治疗指南》(2019版)更新解读[J].肝胆胰外科杂志,2020,32(11):659‑663,666. DOI: 10.11952/j.issn.1007-1954.2020.11.005.
    [12]

    EndoI, ShimadaH, TakimotoA, et al. Microscopic liver metastasis: prognostic factor for patients with pT2 gallbladder carcinoma[J]. World J Surg,2004,28(7):692‑696. DOI: 10.1007/s00268-004-7289-4.

    [13]

    SugitaM, RyuM, SatakeM, et al. Intrahepatic inflow areas of the drainage vein of the gallbladder: analysis by angio-CT[J]. Surgery,2000,128(3):417‑421. DOI:10.1067/msy. 2000.107380.

    [14]

    TsujiT, KanemitsuK, HiraokaT, et al. A new method to establish the rational extent of hepatic resection for advan-ced gallbladder cancer using dye injection through the cystic artery[J]. HPB (Oxford),2004,6(1):33‑66. DOI:10.10 80/13651820410026086.

    [15]

    ChenM,CaoJ,XiangY,et al. Hepatectomy strategy for T2 gallbladder cancer between segment Ⅳb and Ⅴ resection and wedge resection: a propensity score‑matched study[J].Surgery,2021,169(6):1304‑1311. DOI:10.1016/j.surg. 2020.12.039.

    [16]

    GoetzeTO, PaolucciV. [Incidental T1b‑T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor‑results of the German registry][J]. Chirurg,2014,85(2):131‑138. DOI: 10.1007/s00104-013-2587-8.

    [17]

    AokiT, SakamotoY, KohnoY, et al. Hepatopancreaticoduodenectomy for biliary cancer: strategies for near‑zero opera-tive mortality and acceptable long‑term outcome[J]. Ann Surg,2018,267(2):332‑337. DOI:10.1097/SLA.00000000 0 0002059.

    [18] 郭志唐,王琳,魏东,等.联合多脏器切除的T4期胆囊癌扩大根治术临床分析[J].中华普通外科杂志,2018,33(12):1062-1063. DOI: 10.3760/cma.j.issn.1007-631X.2018.12.024.
    [19]

    ShimizuH, KimuraF, YoshidomeH, et al. Aggressive surgical approach for stage Ⅳ gallbladder carcinoma based on Japanese Society of Biliary Surgery classification[J]. J Hepatobiliary Pancreat Surg,2007,14(4):358‑365. DOI:10. 1007/s00534-006-1188-z.

    [20]

    ZhouY, ZhangZ, WuL, et al. A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers[J]. HPB (Oxford),2016,18(1):1‑6. DOI: 10.1016/j.hpb.2015.07.008.

    [21]

    TorresO, AlikhanovR, LiJ, et al. Extended liver surgery for gallbladder cancer revisited: Is there a role for hepatopancreatoduodenectomy?[J]. Int J Surg,2020,82S:82‑86. DOI: 10.1016/j.ijsu.2020.05.085.

    [22]

    EbataT, YokoyamaY, IgamiT, et al. Review of hepatopancreatoduodenectomy for biliary cancer: an extended radical approach of Japanese origin[J]. J Hepatobiliary Pancreat Sci,2014,21(8):550‑555. DOI: 10.1002/jhbp.80.

    [23]

    YamamotoY, SugiuraT, OkamuraY, et al. Is combined pancreatoduodenectomy for advanced gallbladder cancer justified?[J]. Surgery,2016,159(3):810‑820. DOI: 10.1016/j.surg.2015.09.009.

    [24]

    WuX, LiM, WuW, et al. Hepatopancreatoduodenectomy for advanced biliary malignancies[J]. Chin Med J (Engl),2022[2023-01-16]. https://pubmed.ncbi.nlm.nih.gov/35 916551. DOI:10.1097/CM9.0000000000002067. [Online ahead of print].

    [25] 王许安,刘颖斌.肝胰十二指肠切除术治疗胆囊癌的指征和技术要点[J].中国实用外科杂志,2016,36(10):1129‑1131. DOI: 10.7504/CJPS.ISSN1005-2208.2016.10.29.
    [26]

    FuksD, RegimbeauJM, Le TreutYP, et al. Incidental gallbladder cancer by the AFC‑GBC‑2009 Study Group[J]. World J Surg,2011,35(8):1887‑1897. DOI: 10.1007/s00268-011-1134-3.

    [27]

    AraidaT, HiguchiR, HamanoM, et al. Should the extra-hepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey: a multicenter study[J]. Surg Today,2009,39(9):770‑779. DOI: 10.1007/s00595-009-3960-6.

    [28] 刘颖斌,吴向嵩.胆道恶性肿瘤外科治疗的焦点及热点[J].肝胆胰外科杂志,2019,31(2):69‑71,75. DOI:10.11952/j.issn. 1007-1954.2019.02.002.
    [29] 王泽宇,黑振宇,耿亚军,等.基于TNM分期的胆囊癌手术治疗[J].中国实用外科杂志,2021,41(2):236‑238. DOI:10.19 538/j.cjps.issn1005-2208.2021.02.25.
    [30]

    PilgrimCH, UsatoffV, EvansP. Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma[J]. Eur J SurgOncol,2009,35(11):1131‑1136. DOI: 10.1016/j.ejso.2009.02.006.

    [31] 张瑞,吴予涵,张东,等.胆囊癌根治术中淋巴结清扫数目与预后关系的多中心临床研究[J].中华外科杂志,2020,58(4):303‑309. DOI: 10.3760/cma.j.cn112139-20200119-00042.
    [32]

    LeighNL, SolomonD, FeingoldD, et al. Staging gallbladder cancer with lymphadenectomy: the practical application of new AHPBA and AJCC guidelines[J]. HPB (Oxford),2019,21(11):1563‑1569. DOI: 10.1016/j.hpb.2019.03.372.

    [33]

    ShimadaH, EndoI, TogoS, et al. The role of lymph node dissection in the treatment of gallbladder carcinoma[J]. Cancer,1997,79(5):892‑899. DOI:10.1002/(sici)1097-014 2(19970301)79:5<892::aid-cncr4>3.0.co;2-e.

    [34]

    ShiraiY, WakaiT, SakataJ, et al. Regional lymphadenectomy for gallbladder cancer: rational extent, technical details, and patient outcomes[J]. World J Gastroenterol,2012,18(22):2775‑2783. DOI: 10.3748/wjg.v18.i22.2775.

    [35]

    Tjan‑HeijnenV, VialeG. The Lymph node and the metastasis[J]. N Engl J Med,2018,378(21):2045‑2046. DOI:10.10 56/NEJMcibr1803854.

    [36]

    TranTB, NissenNN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance[J]. J Gastrointest Oncol,2015,6(5):452‑458. DOI:10.3978/j.issn.2078-6891. 2015.062.

    [37] 刘颖斌,陈炜.重视胆囊癌的规范化诊断和治疗[J].中华外科杂志,2021,59(4):249‑254. DOI: 10.3760/cma.j.cn112139-20210115-00031.
    [38]

    SasakiR, ItabashiH, FujitaT, et al. Significance of extensive surgery including resection of the pancreas head for the treatment of gallbladder cancer‒from the perspective of mode of lymph node involvement and surgical outcome[J]. World J Surg,2006,30(1):36‑42. DOI: 10.1007/s00268-005-0181-z.

    [39]

    KondoS, NimuraY, HayakawaN, et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma[J]. Br J Surg,2000,87(4):418‑422. DOI: 10.1046/j.1365-2168.2000.01384.x.

    [40]

    KitagawaY, NaginoM, KamiyaJ, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection[J]. Ann Surg,2001, 233(3):385‑392. DOI:10.1097/00000 658-200103000-00013.

    [41]

    NishioH, NaginoM, EbataT, et al. Aggressive surgery for stage Ⅳ gallbladder carcinoma; what are the contraindications?[J]. J Hepatobiliary Pancreat Surg,2007,14(4):351-357. DOI: 10.1007/s00534-006-1187-0.

    [42]

    LiuC, ChenR, ChenY, et al. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)[J]. Int J Oncol,2015, 47(4):1512‑1516. DOI: 10.3892/ijo.2015.3128.

    [43]

    RenT, LiYS, DangXY, et al. Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: results from 24 hospitals in China[J]. World J Gastrointest Surg,2021,13(2):176‑186. DOI: 10.4240/wjgs.v13.i2.176.

    [44]

    LeeSE, JangJY, KimSW, et al. Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea[J]. Ann Surg Oncol,2014,21(11):3654‑3660. DOI:10. 1245/s10434-014-3527-7.

    [45]

    KöhnN, MaubachJ, WarschkowR, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not trans-late to decreased survival: a population‑based, propensity score adjusted analysis[J]. HPB (Oxford),2018,20(11):1073-1081. DOI: 10.1016/j.hpb.2018.05.007.

    [46]

    MakerAV, ButteJM, OxenbergJ, et al. Is port site resection necessary in the surgical management of gallbladder cancer?[J]. Ann Surg Oncol,2012,19(2):409‑417. DOI:10.12 45/s10434-011-1850-9.

    [47]

    EthunCG, PostlewaitLM, LeN, et al. Routine port‑site excision in incidentally discovered gallbladder cancer is not associated with improved survival: a multi‑institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. J Surg Oncol,2017,115(7):805‑811. DOI:10.10 02/jso.24591.

    [48]

    FosterJM, HoshiH, GibbsJF, et al. Gallbladder cancer: defi-ning the indications for primary radical resection and radi-cal re‑resection[J]. Ann Surg Oncol,2007,14(2):833-840. DOI: 10.1245/s10434-006-9097-6.

    [49]

    EthunCG, PostlewaitLM, LeN, et al. Association of optimal time interval to re‑resection for incidental gallbladder cancer with overall survival: a multi‑institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. JAMA Surg,2017,152(2):143‑149. DOI: 10.1001/jamasurg.2016.3642.

    [50]

    DuJ, YangXW, WenZJ, et al. Relationship between prognosis and time interval from cholecystectomy to reoperation in postoperative incidental gallbladder carcinoma[J]. Chin Med J (Engl),2018,131(20):2503‑2505. DOI:10.4103/036 6-6999.243565.

    [51] 杨新伟,栗玉龙,杜晶,等.术后意外胆囊癌再次手术时机探讨[J].中华肝胆外科杂志,2020,26(2):119‑123. DOI:10.37 60/cma.j.issn.1007-8118.2020.02.008.
    [52]

    IsambertM, LeuxC, MétairieS, et al. Incidentally-discovered gallbladder cancer: when, why and which reoperation?[J]. J Visc Surg,2011,148(2):e77‑e84. DOI: 10.1016/j.jviscsurg.2011.02.005.

    [53] 任泰,李永盛,耿亚军,等.中国2010—2017年胆囊癌治疗模式及预后分析[J].中华外科杂志,2020,58(9):697‑706. DOI: 10.3760/cma.j.cn112139-20200403-00279.
    [54]

    ByunY, HanY, KangJS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer[J]. J Hepatobiliary PancreatSci,2019,26(9):416‑425. DOI:10. 1002/jhbp.648.

    [55] 孟强劳,王林,耿智敏.进展期胆囊癌新辅助化疗研究进展[J].中华肝胆外科杂志,2017,23(11):789‑792. DOI: 10.3760/cma.j.issn.1007-8118.2017.11.017.
    [56]

    ChaudhariVA, OstwalV, PatkarS, et al. Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resec-table" gallbladder cancer: the need to define indications[J]. HPB (Oxford),2018,20(9):841‑847. DOI:10.1016/j.hpb. 2018.03.008.

    [57]

    CreasyJM, GoldmanDA, DudejaV, et al. Systemic chemotherapy combined with resection for locally advanced gall-bladder carcinoma: surgical and survival outcomes[J]. J Am CollSurg,2017,224(5):906‑916. DOI:10.1016/j.jamco llsurg.2016.12.058.

    [58]

    SelvakumarVP, ZaidiS, PandeP, et al. Resection after neoadjuvant chemotherapy in advanced carcinoma of the gallbladder: a retrospective study[J]. Indian J SurgOncol,2015,6(1):16‑19. DOI: 10.1007/s13193-015-0377-0.

    [59]

    UlusakaryaA, KarabouéA, CiacioO, et al. A retrospective study of patient‑tailored FOLFIRINOX as a first‑line chemo-therapy for patients with advanced biliary tract cancer[J]. BMC Cancer,2020,20(1):515. DOI: 10.1186/s12885-020-07004-y.

    [60]

    CuiXY, LiXC, CuiJJ, et al. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen[J]. Hepatobiliary Surg Nutr,2021,10(4):498‑506. DOI: 10.21037/hbsn-20-846.

    [61]

    LiM, ZhangZ, LiX, et al. Whole‑exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet,2014,46(8):872‑876. DOI: 10.1038/ng.3030.

    [62]

    JavleM, ChuriC, KangHC, et al. HER2/neu‑directed therapy for biliary tract cancer[J]. J Hematol Oncol,2015,8:58. DOI: 10.1186/s13045-015-0155-z.

    [63]

    YeM, LvJ, XuG, et al. Dual‑targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma[J]. J Int Med Res,2019,47(6):2768‑2777. DOI: 10.1177/0300060519847796.

    [64]

    HardingJ, ClearyJ, ShapiroG, et al. Treating HER2‑mutant advanced biliary tract cancer with neratinib: benefits of HER2‑directed targeted therapy in the phase 2 SUMMIT 'basket' trial[J]. Ann Oncol,2019,30:iv127. DOI: 10.1093/annonc/mdz154.004.

    [65]

    LiM, LiuF, ZhangF, et al. Genomic ERBB2/ERBB3 mutations promote PD‑L1‑mediated immune escape in gallbla-dder cancer: a whole‑exome sequencing analysis[J]. Gut,2019,68(6):1024‑1033. DOI: 10.1136/gutjnl-2018-316039.

    [66]

    ZhangY, ZuoC, LiuL, et al. Single‑cell RNA‑sequencing atlas reveals an MDK‑dependent immunosuppressive environment in ErbB pathway‑mutated gallbladder cancer[J]. J Hepatol,2021,75(5):1128‑1141. DOI:10.1016/j.jhep.2021. 06.023.

    [67]

    SongX, HuY, LiY, et al. Overview of current targeted therapy in gallbladder cancer[J]. Signal Transduct Target Ther,2020,5(1):230. DOI: 10.1038/s41392-020-00324-2.

    [68]

    UenoM, IkedaM, MorizaneC, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non‑randomised, multicentre, open‑label, phase 1 study[J]. Lancet GastroenterolHepatol,2019,4(8):611‑621. DOI: 10.1016/S2468-1253(19)30086-X.

    [69]

    BangYJ, DoiT, BraudFD, et al. 525 Safety and efficacy of pembrolizumab (MK‑3475) in patients (pts) with advan-ced biliary tract cancer: Interim results of KEYNOTE‑028[J]. Eur J Cancer,2015,51(suppl 3):S112.DOI:10.1016/S09 59-8049(16)30326-4.

    [70]

    BangYJ, UenoM, MalkaD, et al. Pembrolizumab (pembro) for advanced biliaryadenocarcinoma: results from the KEYNOTE‑028 (KN028) and KEYNOTE‑158 (KN158) basket studies[J]. J Clin Oncol,2019,37(15):2.

图(1)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-01-08
  • 网络出版日期:  2024-06-24
  • 刊出日期:  2023-01-19

目录

    /

    返回文章
    返回